感谢 隐私政策 Cookie政策 我们有什么能帮上忙吗？ Go to the 2022 edition

ADA 2023

Medfyle Conference Coverage
(可选)
隐私政策.



ADA 2023 Medfyle

Conference Coverage

This activity is supported by educational grants from LILLY and NOVO NORDISK A/S.

Welcome!

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Vivian Fonseca, MD
ADA 2023 Medfyle Conference Coverage Editor

今日之ADA

Welcome to Today@ADA - your fast-track to daily conference highlights, coming direct to you from New Orleans. Our team is on site to bring you their top picks from the American Diabetes Association’s 82nd Scientific Sessions. Each day we’ll showcase a speaker interview and a selection of highlights from key talks, with personal insights and commentaries on how new data impact the diabetes landscape.

play-circle

第一天 1

六月
23
play-circle

第一天 2

六月
24
play-circle

第一天 3

六月
25
play-circle

第一天 4

六月
26

Deep Dives

Interested in learning more about the latest advancements in current, emerging, and novel therapies for T2D, as well as new data on weight-centric management?

摘要

Missed the full presentation? Read at-a-glance summaries from a selection of oral presentations. Don’t forget to download the slides!

T2D & Obesity

Tirzepatide for treating obesity in type 2 diabetes

W. Timothy Garvey, MD, MACE; Matthias Tschöp, MD; Juan Pablo Frias, MD; Naveed Sattar, MD, PhD; Ildiko Lingvay, MD, MPH, MSCS

In adults with obesity and type 2 diabetes, 72 weeks of treatment with tirzepatide 10 mg and 15 mg once weekly led to substantial and clinically meaningful reduction in body weight.

ADA 2023 - Symposium 

SURMOUNT 2 Trial Results and Potential Role of Tirzepatide in Treating Obesity in Type 2 Diabetes

了解更多

01-tirzepatide-for-treating-obesity-in-type2diabetes
T2D & Obesity

Oral Semaglutide for Treatment of Obesity and Type 2 Diabetes

Ildiko Lingvay, MD, MPH, MSCS; Vanita Aroda, MD; Filip Knop, MD, PhD; Julio Rosenstock, MD; Sue Pedersen, MD, FRCPC; Sean Wharton MD, PharmD

OASIS: in adults without type 2 diabetes with overweight or obesity, once daily oral semaglutide 50 mg led to superior and clinically meaningful decrease in body weight vs. placebo. PIONEER PLUS: in adults with inadequately controlled type 2 diabetes oral semaglutide 25 mg and 50 mg were superior to 14 mg in reducing HbA1c and body weight.

ADA 2023 - Symposium 

Oral Semaglutide for Treatment of Obesity and Type 2 Diabetes—Results from OASIS 1 and PIONEER PLUS Trial

了解更多

02-oral-semaglutide-for-treatment-of-obesity-and-type2diabetes
T2D & ASCVD

COORDINATE - Diabetes Study: a coordinated, multifaceted intervention for adults with T2D and atherosclerotic cardiovascular disease

Jennifer Green, MD; Neha Pagidipati, MD, MPH; Adam Nelson, MBBS, MBA, MPH, PhD; Christopher Granger, MD, FACC, FAHA; Ildiko Lingvay, MD, MPH, MSCS; Mikhail N Kosiborod, MD

In adults with T2D and atherosclerotic cardiovascular disease, a coordinated, multifaceted intervention increases the prescription of evidence-based therapies (high-intensity statins, ACEIs/ARBs, and SGLT2is /GLP-1 RAs).

ADA 2023 - Symposium 

COORDINATE - Diabetes Study Results

了解更多

03-coordinate-diabetes-study-a-coordinated-multifaceted-intervention-for-adults-with-t2d-and-atherosclerotic-cardiovascular-disease
查看所有

发帖人

Read at-a-glance summaries from a selection of poster presentations.

T2D Therapy

Once-weekly insulin icodec provides superior glycemic control over once-daily basal insulin

Harpreet S Bajaj, MD, MPH

Insulin icodec with a dosing guide app is superior in HbA1C reduction with low hypoglycemia rates vs. once daily basal insulin analogs in a real-world setting.

ADA 2023 - Poster Session

Superior Glycemic Control with Once-Weekly Insulin Icodec with a Dosing Guide App vs. Once-Daily (OD) Basal Insulin Analogs in Insulin-Naïve T2D—ONWARDS 5

了解更多

p01-once-weekly-insulin-icodec-provides-superior-glycemic-control-over-once-daily-basal-insulin
T2D Therapy

Once weekly insulin icodec vs. insulin glargine U100

Julio Rosenstock, MD

Once weekly insulin icodec significantly improves time in range and time above range compared to insulin glargine U100 with no difference in hypoglycemia.

ADA 2023 - Poster Session

CGM Outcomes and Hypoglycemia Duration with Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 in Insulin-Naïve T2D—ONWARDS 1

了解更多

p02-once-weekly-insulin-icodec-vs-insulin-glargine-u100
T2D & Obesity

Orforglipron vs. placebo and dulaglutide in type 2 diabetes

Juan P. Frias, Stanley H. Hsia, Sarah Eyde, Rong Liu, Xiaosu Ma, Manige Konig, Christof M. Kazda, Edward J. Pratt, Kieren J. Mather, Axel Haupt, Deborah A. Robins

Orforglipron is an oral GLP-1 RA under development for type 2 diabetes and weight loss. This trial showed that this new drug led to significant decreases in HbA1c and body weight with a safety profile consistent with other GLP-1 RAs.

ADA 2023 - Poster Session

Effect of Orforglipron vs. Placebo and Dulaglutide on Glycemic Control and Body Weight in Patients with Type 2 Diabetes

了解更多

p03-orforglipron-vs-placebo-and-dulaglutide-in-type-2-diabetes
查看所有
关于ADA 反馈 My Library

DOWNLOAD THE APP

Enhance your clinical practice with just five minutes of learning, staying up to date with the latest medical research and essential knowledge.


Or visit medfyle.com

Ask the Expert

Have a question? Submit it below.
A selection of the most interesting questions will be answered in a new video. You will receive an email when answers will be published.